CRISPR Therapeutics AG [CRSP] stock is trading at $47.91, down -5.00%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CRSP shares have gain 10.16% over the last week, with a monthly amount glided 8.39%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on February 14, 2025, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $99 from $60. Previously, TD Cowen upgraded its rating to Hold on February 12, 2025, and kept the price target unchanged to $35. On February 03, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $65 on the stock. Needham reiterated its Buy rating and decreased its price target to $84 on August 06, 2024. Rodman & Renshaw initiated its recommendation with a Buy and recommended $90 as its price target on August 02, 2024. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
CRISPR Therapeutics AG [CRSP] stock has fluctuated between $36.52 and $91.10 over the past year. Currently, Wall Street analysts expect the stock to reach $75.67 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $47.91 at the most recent close of the market. An investor can expect a potential return of 57.94% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
CRISPR Therapeutics AG [NASDAQ:CRSP] reported sales of 37.31M for the trailing twelve months, which represents a drop of -82.26%. Gross Profit Margin for this corporation currently stands at -2.27% with Operating Profit Margin at -12.74%, Pretax Profit Margin comes in at -9.9%, and Net Profit Margin reading is -10.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.18 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 46.34 points at the first support level, and at 44.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 50.47, and for the 2nd resistance point, it is at 53.04.
Ratios To Look Out For
For context, CRISPR Therapeutics AG’s Current Ratio is 22.07. Further, the Quick Ratio stands at 22.07, while the Cash Ratio is 3.4. Considering the valuation of this stock, the price to sales ratio is 110.14, the price to book ratio is 2.13.
Transactions by insiders
Recent insider trading involved Kulkarni Samarth, Chief Executive Officer, that happened on Feb 19 ’25 when 18360.0 shares were sold. Chief Executive Officer, Kulkarni Samarth completed a deal on Feb 18 ’25 to sell 11640.0 shares. Meanwhile, Chief Executive Officer Kulkarni Samarth sold 6928.0 shares on Feb 19 ’25.
